maintenance treatment

December 8, 2017

FDA Grants Rubraca Speedy Review for Use as Ovarian Cancer Maintenance Treatment

News

The U.S. Food and Drug Administration (FDA) has granted Priority Review Status to Clovis Oncology’s application to expand its approval for Rubraca (rucaparib) to include recurrent ovarian cancer maintenance treatment. A decision ... Read more

October 11, 2017December 8, 2017

Clovis Seeks FDA Approval for Rubraca as Ovarian Cancer Maintenance Therapy

News

Clovis Oncology seeks to expand its approval for Rubraca (rucaparib) to include maintenance therapy for women with recurrent ovarian cancer who respond to platinum-based chemotherapy. The company, based in Boulder, ... Read more

September 11, 2017September 11, 2017

Rubraca as Maintenance Therapy Seen to Aid Survival Without Disease Progression in Range of Patients

News

Rubraca (rucaparib) maintenance treatment significantly improved survival without further disease progression among ovarian cancer patients taking part in a Phase 3 clinical trial, researchers showed in a presentation at the ongoing European Society ... Read more